STOCK TITAN

[S-8 POS] Renalytix plc American Depositary Shares SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Renalytix plc (RNLX) filed Post-Effective Amendment No. 1 to its Form S-8 (Reg. No. 333-274732). The amendment terminates the effectiveness of the original registration statement and dere­gisters all ordinary shares (£0.0025 par value) that remain unissued under two employee programs: (1) the 2020 Employee Share Purchase Plan and (2) the 2020 Equity Incentive Plan. No new securities will be offered pursuant to these plans under this registration after the filing becomes effective, which occurs automatically upon submission under Rule 464.

The company confirms its status as a non-accelerated filer, smaller reporting company, and emerging growth company. The document is signed by CEO James McCullough in London on 25 July 2025, with no additional signatures required under Rule 478.

Renalytix plc (RNLX) ha depositato la Modifica Post-Efficace N. 1 al modulo S-8 (Reg. N. 333-274732). La modifica cancella l'efficacia della dichiarazione di registrazione originale e deregistra tutte le azioni ordinarie (valore nominale £0,0025) non ancora emesse nell'ambito di due programmi per dipendenti: (1) il Piano di Acquisto Azionario per Dipendenti 2020 e (2) il Piano di Incentivi Azionari 2020. Non saranno offerte nuove azioni tramite questi piani sotto questa registrazione una volta che la modifica diventerà effettiva, il che avviene automaticamente al momento della presentazione secondo la Regola 464.

L'azienda conferma il proprio status di non-accelerated filer, smaller reporting company e emerging growth company. Il documento è firmato dall'Amministratore Delegato James McCullough a Londra il 25 luglio 2025, senza ulteriori firme richieste secondo la Regola 478.

Renalytix plc (RNLX) presentó la Enmienda Post-Efectiva No. 1 a su Formulario S-8 (Reg. No. 333-274732). La enmienda termina la vigencia de la declaración de registro original y cancela el registro de todas las acciones ordinarias (valor nominal de £0.0025) que permanecen sin emitir bajo dos programas para empleados: (1) el Plan de Compra de Acciones para Empleados 2020 y (2) el Plan de Incentivos de Capital 2020. No se ofrecerán nuevos valores bajo estos planes con esta registración una vez que la presentación sea efectiva, lo cual ocurre automáticamente al presentarse bajo la Regla 464.

La compañía confirma su condición de presentador no acelerado, empresa de reporte más pequeña y empresa emergente en crecimiento. El documento está firmado por el CEO James McCullough en Londres el 25 de julio de 2025, sin que se requieran firmas adicionales según la Regla 478.

Renalytix plc (RNLX)는 Form S-8에 대한 사후 효력 수정 제1호 (등록번호 333-274732)를 제출했습니다. 이 수정안은 원래 등록 명세서의 효력을 종료하고 두 가지 직원 프로그램 하에서 미발행 상태인 모든 보통주(액면가 £0.0025)를 등록 말소합니다: (1) 2020 직원 주식 구매 계획 및 (2) 2020 주식 인센티브 계획. 이 제출이 효력을 발생하면, 이는 규칙 464에 따라 자동으로 발생하며, 이후 이 등록 하에서 이들 계획에 따른 새로운 증권은 제공되지 않습니다.

회사는 자신이 비가속 보고자, 소규모 보고 회사, 신생 성장 회사임을 확인합니다. 문서는 2025년 7월 25일 런던에서 CEO 제임스 맥컬러프가 서명했으며, 규칙 478에 따라 추가 서명은 필요하지 않습니다.

Renalytix plc (RNLX) a déposé la modification post-effective n° 1 de son formulaire S-8 (reg. n° 333-274732). Cette modification met fin à l'efficacité de la déclaration d'enregistrement initiale et déréférence toutes les actions ordinaires (valeur nominale de £0,0025) non émises dans le cadre de deux programmes pour employés : (1) le Plan d'achat d'actions des employés 2020 et (2) le Plan d'incitation en actions 2020. Aucune nouvelle valeur mobilière ne sera offerte en vertu de ces plans sous cette inscription une fois que le dépôt deviendra effectif, ce qui se produit automatiquement lors de la soumission selon la Règle 464.

L'entreprise confirme son statut de déposant non accéléré, petite société de reporting et société en croissance émergente. Le document est signé par le PDG James McCullough à Londres le 25 juillet 2025, sans autres signatures requises selon la Règle 478.

Renalytix plc (RNLX) hat die Nachwirkende Änderung Nr. 1 zu seinem Formular S-8 (Reg.-Nr. 333-274732) eingereicht. Die Änderung beendet die Wirksamkeit der ursprünglichen Registrierungserklärung und meldet alle nicht ausgegebenen Stammaktien (Nennwert £0,0025) ab, die unter zwei Mitarbeiterprogrammen verbleiben: (1) dem Mitarbeiter-Aktienkaufplan 2020 und (2) dem Aktienanreizplan 2020. Nach Wirksamwerden dieser Einreichung, was automatisch mit der Einreichung gemäß Regel 464 geschieht, werden keine neuen Wertpapiere unter diesen Plänen angeboten.

Das Unternehmen bestätigt seinen Status als nicht beschleunigter Einreicher, kleinere berichtspflichtige Gesellschaft und wachsendes Unternehmen. Das Dokument wurde am 25. Juli 2025 in London vom CEO James McCullough unterzeichnet, weitere Unterschriften sind gemäß Regel 478 nicht erforderlich.

Positive
  • Deregisters unissued shares, eliminating a source of potential future shareholder dilution.
Negative
  • Reduces share-based compensation flexibility by cancelling registration of plan shares.

Insights

TL;DR – Housekeeping amendment that removes unused equity from registration; negligible operational impact.

This S-8 POS simply withdraws unissued shares tied to Renalytix’s 2020 ESPP and Equity Incentive Plan. The move halts the ability to issue those particular shares, modestly reducing potential future dilution but also limiting equity-based compensation capacity. There are no financial metrics, capital raises, or strategic signals in the filing; therefore, the market impact is expected to be neutral and purely administrative.

Renalytix plc (RNLX) ha depositato la Modifica Post-Efficace N. 1 al modulo S-8 (Reg. N. 333-274732). La modifica cancella l'efficacia della dichiarazione di registrazione originale e deregistra tutte le azioni ordinarie (valore nominale £0,0025) non ancora emesse nell'ambito di due programmi per dipendenti: (1) il Piano di Acquisto Azionario per Dipendenti 2020 e (2) il Piano di Incentivi Azionari 2020. Non saranno offerte nuove azioni tramite questi piani sotto questa registrazione una volta che la modifica diventerà effettiva, il che avviene automaticamente al momento della presentazione secondo la Regola 464.

L'azienda conferma il proprio status di non-accelerated filer, smaller reporting company e emerging growth company. Il documento è firmato dall'Amministratore Delegato James McCullough a Londra il 25 luglio 2025, senza ulteriori firme richieste secondo la Regola 478.

Renalytix plc (RNLX) presentó la Enmienda Post-Efectiva No. 1 a su Formulario S-8 (Reg. No. 333-274732). La enmienda termina la vigencia de la declaración de registro original y cancela el registro de todas las acciones ordinarias (valor nominal de £0.0025) que permanecen sin emitir bajo dos programas para empleados: (1) el Plan de Compra de Acciones para Empleados 2020 y (2) el Plan de Incentivos de Capital 2020. No se ofrecerán nuevos valores bajo estos planes con esta registración una vez que la presentación sea efectiva, lo cual ocurre automáticamente al presentarse bajo la Regla 464.

La compañía confirma su condición de presentador no acelerado, empresa de reporte más pequeña y empresa emergente en crecimiento. El documento está firmado por el CEO James McCullough en Londres el 25 de julio de 2025, sin que se requieran firmas adicionales según la Regla 478.

Renalytix plc (RNLX)는 Form S-8에 대한 사후 효력 수정 제1호 (등록번호 333-274732)를 제출했습니다. 이 수정안은 원래 등록 명세서의 효력을 종료하고 두 가지 직원 프로그램 하에서 미발행 상태인 모든 보통주(액면가 £0.0025)를 등록 말소합니다: (1) 2020 직원 주식 구매 계획 및 (2) 2020 주식 인센티브 계획. 이 제출이 효력을 발생하면, 이는 규칙 464에 따라 자동으로 발생하며, 이후 이 등록 하에서 이들 계획에 따른 새로운 증권은 제공되지 않습니다.

회사는 자신이 비가속 보고자, 소규모 보고 회사, 신생 성장 회사임을 확인합니다. 문서는 2025년 7월 25일 런던에서 CEO 제임스 맥컬러프가 서명했으며, 규칙 478에 따라 추가 서명은 필요하지 않습니다.

Renalytix plc (RNLX) a déposé la modification post-effective n° 1 de son formulaire S-8 (reg. n° 333-274732). Cette modification met fin à l'efficacité de la déclaration d'enregistrement initiale et déréférence toutes les actions ordinaires (valeur nominale de £0,0025) non émises dans le cadre de deux programmes pour employés : (1) le Plan d'achat d'actions des employés 2020 et (2) le Plan d'incitation en actions 2020. Aucune nouvelle valeur mobilière ne sera offerte en vertu de ces plans sous cette inscription une fois que le dépôt deviendra effectif, ce qui se produit automatiquement lors de la soumission selon la Règle 464.

L'entreprise confirme son statut de déposant non accéléré, petite société de reporting et société en croissance émergente. Le document est signé par le PDG James McCullough à Londres le 25 juillet 2025, sans autres signatures requises selon la Règle 478.

Renalytix plc (RNLX) hat die Nachwirkende Änderung Nr. 1 zu seinem Formular S-8 (Reg.-Nr. 333-274732) eingereicht. Die Änderung beendet die Wirksamkeit der ursprünglichen Registrierungserklärung und meldet alle nicht ausgegebenen Stammaktien (Nennwert £0,0025) ab, die unter zwei Mitarbeiterprogrammen verbleiben: (1) dem Mitarbeiter-Aktienkaufplan 2020 und (2) dem Aktienanreizplan 2020. Nach Wirksamwerden dieser Einreichung, was automatisch mit der Einreichung gemäß Regel 464 geschieht, werden keine neuen Wertpapiere unter diesen Plänen angeboten.

Das Unternehmen bestätigt seinen Status als nicht beschleunigter Einreicher, kleinere berichtspflichtige Gesellschaft und wachsendes Unternehmen. Das Dokument wurde am 25. Juli 2025 in London vom CEO James McCullough unterzeichnet, weitere Unterschriften sind gemäß Regel 478 nicht erforderlich.

Registration No. 333-274732

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

POST-EFFECTIVE AMENDMENT NO. 1

TO

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

Renalytix plc

(Exact name of registrant as specified in its charter)

 

England and Wales   Not applicable
(State or other jurisdiction of incorporation)   (I.R.S. Employer Identification No.)

 

2 Leman Street

London E1W 9US

United Kingdom

(Address of principal executive offices) (Zip Code)

 

Renalytix AI plc 2020 Employee Share Purchase Plan

Renalytix AI plc 2020 Equity Incentive Plan

(Full title of the plan)

 

Renalytix AI, Inc.

1460 Broadway

New York, NY 10036

Tel: +1 646 397 3970

(Name, address and telephone number, including area code, of agent for service)
 
Copies to:
 
Mark E. Rosenstein
Derick S. Kauffman
Stevens & Lee, P.C.
620 Freedom Business Center, Suite 200
King of Prussia, PA 19406
(610) 205-6000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒
Smaller reporting company ☒ Emerging growth company ☒  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

This Registration Statement shall become effective upon filing in accordance with Rule 464 promulgated under the Securities Act of 1933, as amended.

 

 

 

 

 

 

DEREGISTRATION OF SHARES

 

Renalytix plc (the “Company”) is filing this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (File No. 333-274732) (the “Registration Statement”), to deregister the offer of the ordinary shares, nominal value £0.0025 per ordinary share, of the Company, registered under the Registration Statement that remain unissued under each of the Renalytix AI plc 2020 Employee Share Purchase Plan, and Renalytix AI plc 2020 Equity Incentive Plan.

 

The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities and the Company hereby terminates the effectiveness of the Registration Statement.

 

1

 

 

SIGNATURES

 

The Registrant. Pursuant to the requirements of the Securities Exchange Act of 1933, as amended, the Registrant certifies that is has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of London, United Kingdom, on July 25, 2025.

 

  RENALYTIX PLC
   
  /s/ James McCullough
  Name:  James McCullough
  Title: Chief Executive Officer and Director

 

No other person is required to sign this Post-Effective Amendment to the Registration Statement in reliance on Rule 478 of the Securities Act of 1933, as amended.

 

2

FAQ

What did Renalytix plc file on July 25 2025?

The company filed Post-Effective Amendment No. 1 to Form S-8 to deregister unissued shares under its 2020 ESPP and Equity Incentive Plan.

How many shares are being deregistered by RNLX?

The exact number is not specified; the amendment removes all remaining unissued ordinary shares registered under the two 2020 plans.

Will Renalytix still issue shares under the 2020 plans?

No. By terminating the registration statement, no additional shares can be issued under those plans via this filing.

Does this filing affect Renalytix’s filer status?

The company remains a non-accelerated filer, smaller reporting company, and emerging growth company, as indicated in the amendment.

Who signed the Post-Effective Amendment for Renalytix?

James McCullough, Chief Executive Officer and Director, signed the document in London.
Renalytix plc American Depositary Shares

NASDAQ:RNLX

RNLX Rankings

RNLX Latest News

RNLX Latest SEC Filings

RNLX Stock Data

17.18M
165.93M
4.51%
4.14%
0.46%
Health Information Services
Services-medical Laboratories
Link
United States
LONDON